Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

(2015) Rohit Loomba et al.   HEPATOLOGY

The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial

(2014) Yumie Takeshita et al.   DIABETOLOGIA

Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent

(2014) Lay T. Gan et al.   JOURNAL OF HEPATOLOGY

Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice

(2013) Kengo Tomita et al.   HEPATOLOGY

Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease

(2013) Noriko Oza et al.   HEPATOLOGY RESEARCH

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis

(2012) Christopher Savard et al.   HEPATOLOGY

Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

(2012) Rebecca M Turner et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial

(2011) Elena Sofer et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial

(2010) Temitope Foster et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet

(2010) D. C. Chan et al.   DIABETES CARE

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study

(2010) Masato Yoneda et al.   HEPATOLOGY RESEARCH

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease

(2010) Hyohun Park et al.   JOURNAL OF GASTROENTEROLOGY

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

(2010) Munechika Enjoji et al.   Lipids in Health and Disease

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-up Study

(2009) Leon A Adams et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Palmitate Induces Insulin Resistance in H4IIEC3 Hepatocytes through Reactive Oxygen Species Produced by Mitochondria

(2009) Seiji Nakamura et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

(2009) Yuichi Nozaki et al.   JOURNAL OF HEPATOLOGY

Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis

(2008) Kristiaan Wouters et al.   HEPATOLOGY

Hepatic steatosis rather than visceral adiposity is more closely associated with insulin resistance in the early stage of obesity

(2008) Taro Wasada et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective

(2008) Mariana Lazo et al.   SEMINARS IN LIVER DISEASE